COVID-19 Vaccines
mRNA, viral vector, protein subunit, and inactivated platforms
This page catalogs 12 COVID-19 vaccine products identified in The Ultimate Vaccine Timeline and cross-referenced with FDA, EMA, and WHO regulatory records. COVID-19 vaccines represent the broadest diversity of platform technologies deployed for a single pathogen, including mRNA, adenovirus vector, inactivated whole-virus, protein subunit, virus-like particle, and intranasal delivery.
Last updated: April 2026.
COVID-19 Vaccine Catalog
| Trade Name | Generic Designation | Manufacturer | Vaccine Type | Regulatory Status & Year | Key Notes |
|---|---|---|---|---|---|
| Comirnaty | BNT162b2 mRNA COVID-19 vaccine | Pfizer-BioNTech | mRNA | FDA Licensed, 2021 | First approved mRNA vaccine; full approval Aug 2021 (≥16y) |
| Spikevax | mRNA-1273 COVID-19 vaccine | Moderna | mRNA | FDA Licensed, 2022 | Full approval Jan 2022; EUA revoked Aug 2025 |
| MNEXSPIKE | COVID-19 vaccine, mRNA | TBD | mRNA | FDA Licensed, 2025 | Newer mRNA COVID-19 vaccine per FDA CBER list |
| Nuvaxovid | NVX-CoV2373 protein subunit COVID-19 vaccine | Novavax | Protein subunit + Matrix-M | FDA Licensed, 2023 | Non-mRNA alternative |
| Vaxzevria | ChAdOx1-S COVID-19 vaccine | AstraZeneca | Adenovirus vector | EMA Authorized, 2021; Withdrawn 2024 | Also known as Covishield outside Europe |
| Covishield | ChAdOx1-S COVID-19 vaccine (SII) | Serum Institute of India | Adenovirus vector | WHO EUL, 2021 | SII-manufactured AstraZeneca vaccine |
| CoronaVac | Inactivated whole-virus COVID-19 vaccine | Sinovac | Inactivated viral | WHO EUL, 2021 | Widely distributed globally by 2021 |
| COVAXIN | BBV152 whole-virion inactivated COVID-19 vaccine | Bharat Biotech | Inactivated viral | WHO EUL, 2021 (suspended 2022) | India-developed |
| Sputnik V | Gam-COVID-Vac adenovirus vector | Gamaleya (Russia) | Adenovirus vector (rAd26+rAd5) | Not WHO prequalified | Heterologous 2-dose vector; never FDA/EMA approved |
| Corbevax | COVID-19 RBD protein subunit vaccine | Biological E | Recombinant protein subunit | India EUA, 2021 | Patent-free RBD protein |
| COVIFENZ | CoVLP plant-derived VLP vaccine | Medicago | Virus-like particle (VLP) | Health Canada, 2022; Withdrawn | Plant-based; Medicago ceased operations 2023 |
| INCOVACC | BBV154 intranasal COVID-19 vaccine | Bharat Biotech | Adenovirus vector (intranasal) | India EUA, 2022 | First approved intranasal COVID-19 vaccine |
Sources
Regulatory data sourced from FDA CBER Vaccines Licensed for Use in the United States (March 2026), EMA Medicines database, and WHO Prequalified Vaccines list. Catalog scope and historical context informed by Khan, Shaz, The Ultimate Vaccine Timeline.